Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Provided By GlobeNewswire
Last update: Sep 29, 2025
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH
Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
Read more at globenewswire.com
